EGFR and colorectal carcinoma: Anti-epidermal growth factor receptor (EGFR) monoclonal antibody treatment, including that with cetuximab and panitumumab, has been reported to improve progression-free survival in advanced CRC patients with wild-type KRAS[5]–[7].